Press room

12th March 2018
Cambridge, UK, 12th March 2018 / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.
1st February 2018
Cambridge, UK, 1st February 2018 / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect.  His appointment strengthens the expanding team of in
23rd January 2018
Cambridge, UK, 23 January 2018 / Domainex Ltd, a privately-owned drug discovery services company, has been awarded £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs).
6th December 2017
Cambridge, UK, 6th December 2017 / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Chris Brown has been appointed Chief Financial Officer with immediate effect.
12th September 2017
Cambridge, UK and Stevenage, UK – 12 September 2017 - Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the
17th May 2017
Domainex signs multi-year agreement with Dotmatics – a leading provider of scientific informatics – to streamline its integrated drug discovery services
30th March 2017
Domainex, a drug discovery services company, is pleased to announce that Dr Timo Veromaa has been appointed Executive Chairman with immediate effect.
7th March 2017
Domainex launched its fragment screening service, FragmentBuilder, and is the first CRO in the UK to offer MicroScale Thermophoresis (MST) as part of drug discovery services.
15th December 2016
Domainex has purchased a Monolith NT. Automated instrument, using MicroScale Thermophoresis (MST) technology for high-throughput fragment-based drug discovery.

Pages